The Russian invasion of Ukraine, covid, and low rates have lead to significant commodity price increases across the board.
Ethical Equities Investing
EarlyPay (ASX: EPY) is growing profits strongly and recently upgraded guidance, but the business still faces notable risks.
Strong growth in H1 FY 2022 supports the view that Objective Corporation is one of the highest quality ASX business, but can it justify the share price?
As a general rule, I try not to sell anything on big sell off days. Rather, I bottle up the impulse and let it out on a day when the stocks are bouncing (if at all).
Kip McGrath Education Centres (ASX: KME) is on the verge of reaping the benefits of its corporate centre strategy.
PTB Group (ASX: PTB) achieved record revenue in H1 FY 2022 but longer term growth will rely on acquisitions…
Dicker Data (ASX: DDR) achieved another year of very strong profit growth, assisted by the acquisition of Exeed.
Camplify revenue growth of over 100% will catch investors eye, but the devil is in the detail…
Sequoia Financial Group (ASX: SEQ) reported strong growth and has a very believable plan to keep it going for years to come.
The Ebos Group half year report showed decent growth, both organic and through acquisitions. But the Ebos share price is up, leading to a lower dividend yield.
My analysis of the Pro Medicus half year results suggest that the business is improving in quality as it grows.
Here is a list of ASX Small Cap Stocks results reporting dates, plus links to their results presentations, collated for your convenience.
The Audinate (ASX:AD8) H1 FY 2022 results were subdued at first glance, but key metrics imply the business continues to improve in quality.
Nanosonics shares dropped this morning when it updated the market on its half year revenue, and its distribution agreement with GE Healthcare.
Energy One’s acquisition of CQ Energy should create growth opportunities in renewable energy, but it also brings notable risks.
Quarterly reports of Rightcrowd, IntelliHR and Volpara update us on free cash flow and annualised recurring revenue growth…
The Genetic Signatures (ASX:GSS) share price has dropped almost 10% despite reporting record receipts from customers.